Pharmamarketeer

AstraZeneca presents advances in improving treatment options for ovarian, lung cancer patients at ESMO 2018 Congress

AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the European Society of Medical Oncology (ESMO 2018) Congress in Munich, Germany, 19-23 October.

Reageer

Medhc-fases-banner
Advertentie(s)